文献速递临床试验与 GCP基础与转化研究

心脏磁共振指导射血分数36%至50%患者除颤器植入的随机临床试验

Cardiovascular Magnetic Resonance to Guide Defibrillator Implantation for LVEF of 36% to 50%: The CMR GUIDE Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-08-28

这项开放标签随机临床试验在18个中心纳入353例LVEF 36%–50%且心脏磁共振显示心肌瘢痕的患者,比较预防性ICD与植入式循环记录仪。中位随访6.3年,ICD未降低心源性猝死或血流动力学显著室性心律失常的复合终点(HR 0.76,95%CI 0.37–1.58),但心源性猝死单独终点在ICD组更低。

要点

  • LVEF 36%–50%伴心肌瘢痕者,ICD未显著降低SCD或HSVA复合终点。
  • ICD组心源性猝死发生率低于ILR组(HR 0.26,95%CI 0.07–0.95)。
  • 预设亚组分析提示年龄<70岁患者可能获益,≥70岁未见获益。

核心结论

  • 在LVEF 36%–50%且存在心肌瘢痕的患者中,预防性ICD植入未降低心源性猝死或血流动力学显著室性心律失常的复合终点。

研究设计与样本

  • 开放标签随机临床试验于2015至2022年入组,在澳大利亚、德国和英国18个中心进行。
  • 纳入353例缺血性或非缺血性心肌病、LVEF 36%–50%、CMR defined心肌瘢痕且接受指南导向药物治疗的成人。
  • 随机分为预防性ICD组(n=180)与植入式循环记录仪组(n=173),中位随访6.3年(IQR 4.8–7.6年)。

主要发现

  • 主要复合终点在ICD组发生14例(7.8%),ILR组16例(9.2%),HR 0.76(95%CI 0.37–1.58)。
  • 心源性猝死在ICD组3例(1.7%),ILR组10例(5.8%),HR 0.26(95%CI 0.07–0.95)。
  • 血流动力学显著室性心律失常在ICD组12例(6.7%),ILR组6例(3.5%),HR 1.77(95%CI 0.65–4.81)。
  • 全因死亡、心血管死亡和心衰相关住院率两组相似。

临床怎么用

  • 对于LVEF 36%–50%伴心肌瘢痕患者,不能仅凭瘢痕依据普遍推荐预防性ICD植入。
  • 年龄<70岁患者可能从ICD植入中获益,≥70岁患者未见获益甚至可能不利,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Current guidelines do not recommend primary prevention implantable cardioverter-defibrillators (ICDs) unless a patient's left ventricular ejection fraction (LVEF) is 35% or less. Many sudden cardiac deaths (SCD) occur when LVEF is 36% to 50%. Myocardial scar (a key arrhythmic substrate) can be assessed by late gadolinium enhancement on cardiovascular magnetic resonance (CMR), but robust evidence is lacking regarding a scar-based approach to ICD insertion. OBJECTIVE: To determine whether implantation of ICDs reduces SCD or hemodynamically significant ventricular arrhythmia (HSVA) in patients with an LVEF of 36% to 50% and myocardial scar. DESIGN, SETTING, AND PARTICIPANTS: An open-label randomized clinical trial enrolled adults between 2015 and 2022 who had ischemic or nonischemic cardiomyopathy, an LVEF of 36% to 50%, CMR-defined myocardial scar, and were receiving guideline-directed medical therapy at 18 sites in Australia, Germany, and the UK. Follow-up assessments were completed in 2026. INTERVENTIONS: A primary prevention ICD (n = 180) vs an implantable loop recorder (ILR) (n = 173). MAIN OUTCOMES AND MEASURES: The primary composite outcome was SCD or HSVA. Five secondary outcomes were evaluated: SCD, HSVA, heart failure-related hospitalization, cardiovascular mortality, and all-cause mortality. RESULTS: Of 353 patients randomized (median age, 65 years [IQR, 57-61 years]; 18% female; and 72% had an ischemic etiology), 70% had an LVEF of 40% or greater. The median follow-up was 6.3 years (IQR, 4.8-7.6 years). The primary composite outcome occurred in 14 patients (7.8%) in the ICD group compared with 16 patients (9.2%) in the ILR group (hazard ratio [HR], 0.76 [95% CI, 0.37-1.58]). For the individual components of the primary composite outcome, SCD occurred in 3 patients (1.7%) vs 10 patients (5.8%) in the ILR group (HR, 0.26 [95% CI, 0.07-0.95]) and HSVA occurred in 12 patients (6.7%) vs 6 patients (3.5%), respectively (HR, 1.77 [95% CI, 0.65-4.81]). The rates for all-cause mortality, cardiovascular mortality, and heart failure-related hospitalization were similar between groups. In a prespecified analysis of 6 subgroups, the primary outcome occurred less often in patients younger than 70 years in the ICD group (3.3%) vs patients in the ILR group (10.0%) (HR, 0.28 [95% CI, 0.09-0.89]) but not in those aged 70 years or older (16.9% vs 7.5%, respectively) (HR, 2.33 [95% CI, 0.75-7.26]; P = .01 for interaction). CONCLUSIONS AND RELEVANCE: Implantation of an ICD did not reduce the composite outcome of SCD or HSVA in patients with an LVEF of 36% to 50% and myocardial scar. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01918215.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Selvanayagam JB, Cleland JGF, Hillis GS, et al. Cardiovascular Magnetic Resonance to Guide Defibrillator Implantation for LVEF of 36% to 50%: The CMR GUIDE Randomized Clinical Trial. JAMA. 2026. PMID: 42663169. doi:10.1001/jama.2026.17078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。